3.91 USD
▲+0.13+3.44%
盘后 3.84 -1.79%
2026-09-15
市值
$410.22M
市盈率
—
EPS
-1.93
股息率
—
52 周区间
2.72 – 6.42
成交量
856.56K
Beta
0.75
目标价
14.40
52W 低 2.7252W 高 6.42
价格走势
公司简介
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.